BiotechTube

Fulvestrant

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Female Breast Carcinoma

Conditions

Female Breast Carcinoma, Female Ductal Carcinoma In Situ

Trial Timeline

Mar 1, 2016 → Aug 13, 2020

NCT ID
NCT02540330

About Fulvestrant

Fulvestrant is a phase 2 stage product being developed by Atossa Therapeutics for Female Breast Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02540330. Target conditions include Female Breast Carcinoma, Female Ductal Carcinoma In Situ.

What happened to similar drugs?

2 of 15 similar drugs in Female Breast Carcinoma were approved

Approved (2) Terminated (0) Active (13)
🔄Gemcitabine + liposomal doxorubicinEli LillyPhase 3
✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
🔄Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
🔄Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
🔄Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02540330Phase 2Terminated

Competing Products

20 competing products in Female Breast Carcinoma

See all competitors
ProductCompanyStageHype Score
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
ASP3325 + PlaceboAstellas PharmaPhase 1
29
EnsitrelvirShionogiPhase 1
29
Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
39
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
44
Abemaciclib, durvalumab and aromatase inhibitorEli LillyPhase 1
21
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
29
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
29
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280 tabletsJiangsu Hengrui MedicinePhase 2
35
SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
40
SHR3162Jiangsu Hengrui MedicinePhase 1
25
AZD3293 + PlaceboAstraZenecaPhase 1
29
Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3
40
AZD2516 + PlaceboAstraZenecaPhase 1
29
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Dapagliflozin + Metformin + Dapagliflozin + MetforminAstraZenecaPhase 1
29